Abstracts

HIV-1 Infection and Alzheimer’s Disease Pathobiology in a Novel Humanized APP-Knock in Mouse Model

Background: The prevalence of aged-associated Alzheimer’s-like disease is increasing in people living with HIV. Disease mechanisms are linked to interactions between progressive HIV infection, neuroinflammation, CD4+ T cell depletion, and aggregation of misfolded proteins. Sustained viral replication in the brain and immune dysfunction accelerates neuroinflammation. Simultaneous HIV and Alzheimer’s disease (AD)studies have been limited due…

SARS-CoV-2 Nucleocapsid Antigen is Not Detected in the CSF During Long COVID

Background: SARS-CoV-2 viral protein persistence has been suggested as a possible cause of post acute sequelae of COVID-19. We previously showed that some individuals with neuropsychiatric symptoms after COVID-19 had persistent anti-SARS-CoV-2 nucleocapsid antibodies in the cerebrospinal fluid (CSF) several months after COVID-19. However, it is unknown whether this is driven by persistence of SARS-CoV-2…

The Association Between Prior SARS-CoV-2 Infection and Incidence of Stroke

Background: Individuals with COVID-19 have an increased incidence of several comorbid conditions including diabetes and acute myocardial infarction. The association of COVID-19 infection with stroke is controversial, with some studies demonstrating a higher risk and other studies showing no association or even a protective effect. We sought to determine the association between COVID-19 infection and…

Long-Acting Dolutegravir Formulation Reduces Fetal Drug Exposure

Background: Dolutegravir (DTG) is a preferred first-line antiretroviral for the treatment of people living with human immunodeficiency virus type one (PLWHIV). Fifteen million PLWHIV world-wide are expected to be treated with DTG regimen by 2025. This includes pregnant women, who remain a significant infected population. Widespread DTG usage is linked to its high potency, barrier…

Pharmacogenetics of Early Neuropsychiatric Adverse Events After Switching to DTG in Second-Line ART

Background: Dolutegravir is associated with neuropsychiatric adverse events (NPAEs). We characterised associations between genetic polymorphisms and early NPAEs in adults failing efavirenz-based antiretroviral therapy and switching to a dolutegravir-based regimen. Methods: We conducted a pharmacogenetic sub-study of participants enrolled into the ARTIST clinical trial, who were switched from tenofovir-emtricitabine-efavirenz to tenofovir-lamivudine-dolutegravir and randomised to supplementary…

Inflammation and Cognition Associations in Young Adults With Perinatal HIV Exposure and/or Infection

Background: Children with perinatal HIV exposure, particularly those with HIV infection, are at risk for worse cognitive outcomes compared to unexposed children. Inflammation is a potential risk factor for worse cognitive outcomes in populations with HIV, but no studies have evaluated this association within young adults with perinatal HIV (YAPHIV) or perinatal HIV exposure but…

CD4 Count Predicts Longitudinal Trajectories of Central Executive Network Connectivity in PLWH

Background: The brain’s central executive network (CEN) plays a key role in the pathogenesis of depression, problematic substance use, and cognitive impairment, all of which are common comorbidities of HIV. Previous cross-sectional research has reported that resting-state functional connectivity (rsFC) in the CEN is lower in people living with HIV (PLWH) compared to participants without…

The Humanized DRAGA Mouse as a Model for HIV Latency and Cure

Background: HIV infection is now a chronic disease due to the availability of antiretroviral therapy (ART) which suppresses plasma viral loads to below the limit of detection and prevents AIDS. However, the virus establishes latency and persists, a clear barrier to curing HIV. Interruption of ART causes viral rebound and thus requires a lifetime of…

Drug-Controlled Anti-PD-1 CAR T-Cells to Target the Replication-Competent Reservoir in Tfh Cells

Background: Programmed cell death protein 1 (PD-1) is an immune checkpoint marker expressed on memory T cells and enriched in latently-infected CD4+ T cells and T follicular helper cells (TFH) containing replication-competent human immune deficiency virus 1 (HIV) provirus in people with HIV on antiretroviral therapy (ART). We recently tested a novel anti-PD-1 chimeric antigen…